GlassScriptPhysician profile
Christopher L Wathier
NPI 1295724664
$2,838.93
in general payments reported to CMS, 2019-2025
25 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $729 · 2021: $39.87 · 2022: $294 · 2023: $549 · 2024: $670 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.71 | 2019-2022 | |
| Amgen INC. | $315.97 | 2019-2024 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $278.32 | 2019-2022 | |
| Novo Nordisk INC | $270.54 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.26 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $242.03 | 2019-2024 | Linzess, Viberzi, Ubrelvy |
| Pfizer INC. | $204.84 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $115.68 | 2019-2024 | |
| Mylan Specialty L.P. | $98.71 | 2020-2024 | Yupelri |
| Amarin Pharma, INC. | $84.62 | 2019-2020 | |
| Axsome Therapeutics, INC. | $76.94 | 2023-2024 | Sunosi |
| Abbott Laboratories | $74.30 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $70.28 | 2025 | |
| Lundbeck LLC | $68.79 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $60.95 | 2020-2024 | Mounjaro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $56.97 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $56.88 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $36.68 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $29.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.91 | 2023 | Trintellix |
| Sumitomo Pharma America, INC. | $23.36 | 2024 | Gemtesa |
| Allergan, INC. | $22.14 | 2020 | |
| Nestle Healthcare Nutrition INC. | $21.85 | 2020 | |
| Viatris Specialty LLC | $20.46 | 2025 | Yupelri |
| Kci USA, INC. | $17.05 | 2023 | Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wathier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.